First-Line Treatment of Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) with Fludarabine, Cyclophosphamide, and Rituximab (FCR Regimen)

A clinical practice guideline for patients with newly diagnosed chronic lymphocytic leukemia (CLL). The guideline examines first-line treatment of CLL with fludarabine, cyclophosphamide, and rituximab (FCR Regimen). Outcomes of interest include progression-free and overall survival.